Eiko Lifesciences Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Eiko Lifesciences Ltd. on BSE

Load latest

Eiko Lifesciences Ltd.

17 Apr 2023

56.99

3.51%

Corp. Note

Eiko Lifesciences Ltd - 540204 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyEiko Lifesciences Ltd 2CIN NO.L65993MH1977PLC258134 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.05 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Avi Mundecha Designation: Company Secretary and Compliance Officer EmailId: investor.relations@eikolifesciences.com Name of the Chief Financial Officer: Jaid Ismail Kojar Designation: Cheif Financial Officer EmailId: business@eikolifesciences.com Date: 17/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Eiko Lifesciences Ltd.

08 Apr 2023

56.99

3.51%

Company Update

Eiko Lifesciences Ltd - 540204 - Certificate Under Reg.40 (9) Of SEBI (LODR) Regulations, 2015 For …

BSE India

Pursuant to Regulation 40 (10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed the Certificate for the year ended 31st March, 2023 issued by Shravan A. Gupta & Associates, Practicing Company Secretary, for the year ended 31.3.2023 in compliance with Regulation 40 (9) of the above-mentioned Regulations, for your information and record.

pdf

Eiko Lifesciences Ltd.

06 Apr 2023

56.99

3.51%

Company Update

Eiko Lifesciences Ltd - 540204 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended March 31, 2023

pdf

Eiko Lifesciences Ltd.

06 Apr 2023

56.99

3.51%

Company Update

Eiko Lifesciences Ltd - 540204 - Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And …

BSE India

Please find enclosed herewith the Compliance Certificate under Regulation 7 (3) of the SEBI (LODR) Regulations, 2015 for the year ended 31st March, 2023.

pdf

Eiko Lifesciences Ltd.

30 Mar 2023

56.99

3.51%

SAST

Eiko Lifesciences Ltd - 540204 - Closure of Trading Window

BSE India

Pursuant to the Internal Code of Conduct for Prevention of Insider Trading framed by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015 (as amended), please note that the "Trading Window" for purchasing/ selling/ dealing in the shares of the Company shall remain closed effective from April 1, 2023 for designated person (and their immediate relatives) and will be re-opened 48 hours after announcement of the audited financial results of the Company for the Quarter and year ending March 31, 2023 to the Stock Exchange.

pdf

Eiko Lifesciences Ltd.

25 Mar 2023

56.99

3.51%

Company Update

Eiko Lifesciences Ltd - 540204 - Announcement under Regulation 30 (LODR)-Updates on Acquisition

BSE India

Further to our letter dated March 17, 2022, we would like to inform that the Company has completed the acquisition of the following: 1. Acquisition of 5% stake of 'Vivacious Pharmatex Private Limited' ('VPPL') by way of transfer of shares from the existing shareholders cum Directors of the VPPL to Eiko LifeSciences Ltd.

pdf

Eiko Lifesciences Ltd.

17 Mar 2023

56.99

3.51%

Company Update

Eiko Lifesciences Ltd - 540204 - Business Update

BSE India

Business Update

pdf

Eiko Lifesciences Ltd.

17 Mar 2023

56.99

3.51%

Company Update

Eiko Lifesciences Ltd - 540204 - Announcement under Regulation 30 (LODR)-Acquisition

BSE India

The Meeting of the Board of Directors of the Company held today i.e., on Friday, 17th March, 2023 at 2:00 P.M. the Board, inter-alia, considered and approved the following. 1. Considered, approved and signed the Memorandum of Understanding (MOU) cum Share Purchase Agreement dated 17th March, 2023 with 'Vivacious Pharmatex Private Limited' ('VPPL') 2. Acquisition of 5% stake of 'Vivacious Pharmatex Private Limited' ('VPPL') by way of transfer of shares from the existing shareholders cum Directors of the VPPL at a total consideration not exceeding Rs. 5.10 Lacs. Ref. Annexure A & B for details.

pdf

Eiko Lifesciences Ltd.

06 Mar 2023

56.99

3.51%

AGM

Eiko Lifesciences Ltd - 540204 - Disclosure Of Voting Results Of Postal Ballot (Regulation 44(3) Of …

BSE India

This is further to our letter dated 01st February 2023 submitting the postal Ballot Notice for seeking approval of members of the Company by way of Ordinary Resolution for 1. Increase in Authorised Share Capital of the Company. 2. Alteration of the Capital Clause of Memorandum of Association of the Company. The resolution placed through the Postal Ballot was passed with the requisite majority. Further in terms of Section 108 of the Companies Act, 2013 and rules made thereunder, the resolutions is deemed to be passed on the last date of e-voting, i.e., on 04th March 2023

pdf

Eiko Lifesciences Ltd.

06 Mar 2023

56.99

3.51%

SAST

Eiko Lifesciences Ltd - 540204 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Laxmikant Kabra HUF

pdf

Is Narendra Investments (Delhi) Ltd. worth buying?

11 Votes:

Buy 54.55%

Sell 27.27%

Hold 18.18%